What is Alnylam Pharmaceuticals's revenue?

Alnylam Pharmaceuticals (ALNY) generated $4.3B in revenue over the trailing twelve months, up 82.6% year over year.

Is Alnylam Pharmaceuticals profitable?

Alnylam Pharmaceuticals reported $502.3M in net income over the trailing twelve months, a 11.7% net margin.

What are Alnylam Pharmaceuticals's profit margins?

Gross margin is 81.0% and operating margin is 17.5%, with a 11.7% net margin.

What is Alnylam Pharmaceuticals's earnings per share?

Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $3.66.

Where does Alnylam Pharmaceuticals's income statement data come from?

Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Alnylam Pharmaceuticals ALNY Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$4.29B+15.4%	$3.71B+15.7%	$3.21B+30.4%	$2.46B+4.8%	$2.35B+4.4%
Total cost of revenue	$814.5M+20.3%	$677.17M+32.2%	$512.09M+29.0%	$396.84M+23.2%	$322.08M+5.1%
Gross profit	$3.47B+14.3%	$3.04B+12.6%	$2.7B+30.6%	$2.07B+1.9%	$2.03B+4.3%
Gross margin	81%-0.8pp	81.8%-2.3pp	84%+0.2pp	83.9%-2.4pp	86.3%-0.1pp
Research and development	$1.42B+7.6%	$1.32B+5.8%	$1.25B+7.6%	$1.16B+2.6%	$1.13B+0.4%
Selling, general and administrative	$1.29B+6.8%	$1.21B+2.5%	$1.18B+9.4%	$1.08B+7.5%	$1B+3.0%
Total costs & expenses	$3.53B+10.0%	$3.21B+9.1%	$2.95B+11.5%	$2.64B+7.3%	$2.46B+1.6%
Operating income	$752.14M+50.0%	$501.58M+89.5%	$264.7M+247%	-$180.19M-56.2%	-$115.37M+34.8%
Operating margin	17.5%+4.0pp	13.5%+5.3pp	8.2%+15.6pp	-7.3%-2.4pp	-4.9%+3.0pp
Interest expense	$219.33M+5.3%	$208.35M+14.5%	$181.92M+5.8%	$171.9M+4.2%	$164.91M+16.3%
Other income (expense), net	-$240.61M-12.4%	-$214.07M+16.8%	-$257.42M-60.7%	-$160.16M+20.2%	-$200.78M-0.1%
Income before income taxes	$511.53M+77.9%	$287.5M+3,847%	$7.29M+102%	-$340.35M-7.7%	-$316.16M+16.2%
Income tax expense	——	——	-$75.51M-24.8%	-$60.49M+29.4%	-$85.68M+13.6%
Net income	$502.34M+80.6%	$278.1M+236%	$82.79M+130%	-$279.86M-21.4%	-$230.47M+17.1%
Net margin	11.7%+4.2pp	7.5%+4.9pp	2.6%+13.9pp	-11.4%-1.6pp	-9.8%+2.6pp
Diluted earnings per share	$3.66+82.1%	$2.01+272%	$0.54+125%	-$2.17-21.2%	-$1.79+17.5%
EBITDA	$806.94M+44.8%	$557.24M+73.6%	$321.02M+360%	-$123.69M-114%	-$57.82M+51.9%
EBITDA margin	18.8%+3.8pp	15%+5.0pp	10%+15.0pp	-5%-2.6pp	-2.5%+2.9pp
EBIT	$752.14M+50.0%	$501.58M+89.5%	$264.7M+247%	-$180.19M-56.2%	-$115.37M+34.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Alnylam Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alnylam Pharmaceuticals's revenue?: Alnylam Pharmaceuticals (ALNY) generated $4.3B in revenue over the trailing twelve months, up 82.6% year over year.
Is Alnylam Pharmaceuticals profitable?: Alnylam Pharmaceuticals reported $502.3M in net income over the trailing twelve months, a 11.7% net margin.
What are Alnylam Pharmaceuticals's profit margins?: Gross margin is 81.0% and operating margin is 17.5%, with a 11.7% net margin.
What is Alnylam Pharmaceuticals's earnings per share?: Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $3.66.
Where does Alnylam Pharmaceuticals's income statement data come from?: Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.